๊ธฐ๋ณธ ์ •๋ณด
  • ์ œํ’ˆ๋ช… :: ์†Œ๋ก ๋„
  • ๋ถ„๋ฅ˜ :: ํ•ญ์—ผ์ฆ์ œ > ์Šคํ…Œ๋กœ์ด๋“œ์„ฑ ํ•ญ์—ผ์ฆ์ œ
  • ํŠน์ง• :: ์†Œ์—ผ, ๋ฉด์—ญ ์–ต์ œ, ํ•ญ์•” ๋“ฑ.. but ๊ฐ์—ผ์ผ ๋•Œ๋Š” ์‚ฌ์šฉ ๊ธˆ์ง€.
  • ์ž„์ƒ ::

(From ๋‚จ๋‚ด1(A) - 03. ์›๋ฐœ์„ฑ ๋ฉด์—ญ๋งค๊ฐœ์งˆ๋ณ‘์˜ ์•ฝ๋ฌผ ์น˜๋ฃŒ )

1๏ธโƒฃ Glucocorticoids (PDS = [Solondo])

  • Effective + Rapid acting + Inexpensive = ๐Ÿ‘

  • PDS(prednisolone) ์ด์šฉ์ด 90% ์ด์ƒ

  • ๊ฐ€๋Šฅํ•˜๋ฉด ๊ฒฝ๊ตฌ ํˆฌ์—ฌ๊ฐ€ ์ด์ƒ์ , ์ฃผ์‚ฌ์ œ๋กœ๋Š” dexamethasone ๊ฐ€๋Šฅ

  • ๊ธฐ์ „ : cytosolic glucocorticoid receptor์— ๋ถ€์ฐฉํ•˜์—ฌ โ†’ ํ•ต์œผ๋กœ ์ด๋™ โ†’ DNA์— ๋ถ€์ฐฉํ•˜์—ฌ DNA ์ „์‚ฌ๋ฅผ ๋ฐฉํ•ด

  • ์ดˆ๊ธฐ ํšจ๊ณผ : ์ ํ˜ˆ๊ตฌ ํƒ์‹ ์ž‘์šฉ์˜ ๋ฐฉํ•ด (rapid decrease in the phagocytic activity)

  • ์žฅ๊ธฐ ํšจ๊ณผ : ์„ธํฌ์„ฑ ๋ฉด์—ญ์˜ ์–ต์ œ (suppression of cell-mediated immunity)

    • ์„ธํฌ๋ง‰์˜ ์•ˆ์ •ํ™” | phospholipase A2์˜ ์–ต์ œ | cytokine(IL-1, IL-6) ๋ฐฉ์ถœ ๊ฐ์†Œ | Fc receptor ๋ฐœํ˜„ ๊ฐ์†Œ

Prednisolone (> Prednisone)

  • Intermediate-acting | alternate day (๊ฒฉ์ผ ๋ณต์šฉ) | 2-2.2 mg/kg/day PO(=๊ฒฝ๊ตฌ)
  • Predisone์ด ๊ฐ„์—์„œ ๋Œ€์‚ฌ๋˜๋ฉด prednisolone. -solone์˜ ์ƒ์ฒด์ด์šฉ๋ฅ ์ด ํ›จ์”ฌ ๋†’๊ณ , ๊ตญ๋‚ด์—๋Š” -solone ์ œ์ œ๋งŒ ์žˆ์Œ.
  • ๊ณ ์–‘์ด๋Š” ๋” ๋†’์€ ์ €ํ•ญ์„ฑ์„ ๊ฐ€์ง.
    • 2๋ฐฐ ์šฉ๋Ÿ‰ ํˆฌ์—ฌ (2-4 mg/kg/day)
    • 4 mg/week dexamethasone (ํ•œ ๋ฒˆ์— ๊ธธ๊ฒŒ but ์ž˜ ์“ฐ๋Š” ๋ฐฉ๋ฒ•์€ ์•„๋‹˜)
  • Septic shock, ๋ถ€์‹  ์งˆ๋ณ‘, ํ˜ธํก๊ธฐ ์งˆํ™˜, ๊ฐ„, ์œ„์žฅ๊ด€, ๋ฉด์—ญ๋งค๊ฐœ์งˆ๋ณ‘, ํ”ผ๋ถ€๋ณ‘, ํ•ญ์•”, ์—ผ์ฆ ์™„ํ™”, ์†Œ์–‘๊ฐ ๊ฐ์†Œ ๋“ฑ ๋‹ค์–‘ํ•œ ํšจ๊ณผ๊ฐ€ ์žˆ์œผ๋‚˜, ๊ฐ์—ผ์ผ ๋•Œ๋Š” ๊ถŒ์žฅ๋˜์ง€ ์•Š๋Š”๋‹ค.
์žฅ๊ธฐ ๋ถ€์ž‘์šฉ (์ฟ ์‹ฑ ์ฆ์ƒ ์œ ์‚ฌ)
polydipsia/polyuria (๋‹ค์Œ/๋‹ค๋‡จ)
panting (ํ—ฅํ—ฅ๊ฑฐ๋ฆผ)
weakness (ํ—ˆ์•ฝ)
dermatologic changes (ํ”ผ๋ถ€ ๋ณ€ํ™”)
predisposition to infection (๊ฐ์—ผ์— ์ทจ์•ฝ)
gastrointestinal hemorrhage (์œ„์žฅ๊ด€ ์ถœํ˜ˆ)
muscle atrophy (๊ทผ์œก ์œ„์ถ•)
๋œ ํ”ํ•˜๊ฒŒ๋Š”..
insulin resistance (์ธ์А๋ฆฐ ์ €ํ•ญ์„ฑ)
hyperglycemia (๊ณ ํ˜ˆ๋‹น์ฆ)
vacuolar hepatopathy (๊ณตํฌ์„ฑ ๊ฐ„๋ณ‘์ฆ)
hypercoagulability (๊ณผ์‘๊ณ ) : TEG(thromboelastography)๋กœ ๊ฒ€์‚ฌ
* ํ˜ˆ๋‹น์„ ๋†’์ด๊ธฐ ๋•Œ๋ฌธ์— ๋‹น๋‡จ ํ™˜์ž์—์„œ ์ฃผ์˜

  • ๋ถ€์ž‘์šฉ ์ตœ์†Œํ™” + ํšจ๊ณผ ๊ทน๋Œ€ํ™”๋ฅผ ์œ„ํ•ด
    • ๊ณ ์šฉ๋Ÿ‰(์ •๋Ÿ‰) ์œผ๋กœ ์‹œ์ž‘ํ•˜๋˜ (high doses initially)
    • ์ ์ฐจ ์ค„์—ฌ์„œ ์งˆ๋ณ‘์„ ํ†ต์ œํ•  ์ˆ˜ ์žˆ๋Š” ์ตœ์†Œ ์šฉ๋Ÿ‰์— ๋„๋‹ฌ (lowest dose possible)
    • short-acting์ด ๊ถŒ์žฅ๋˜๋ฉฐ, alternative-day therapy (๊ฒฉ์ผ ํˆฌ์•ฝ)์ด ์ข‹๋‹ค.
    • ๋‹จ๊ธฐ๊ฐ„์— ๊ธ‰ํ•˜๊ฒŒ ์•ฝ์„ ์ค„์ด๋ฉด ์žฌ๋ฐœ ์œ„ํ—˜์ด ๋†’์•„์ง€๋ฏ€๋กœ, ์ฒœ์ฒœํžˆ ์ค„์ด๋„๋ก ํ•œ๋‹ค (slowly tapered) : ํ•œ ๋‹ฌ์— ๊ธฐ์กด ๋Œ€๋น„ 50% ์ด์ƒ ์ค„์ด์ง€ ์•Š๋„๋ก ํ•œ๋‹ค. (๋ณดํ†ต 2์ฃผ์— 1๋ฒˆ tapering)
  • ๊ณ ์–‘์ด์—์„œ๋Š” ๋ถ€์ž‘์šฉ์ด ๋œํ•œ ํŽธ.
  • Steroid ์•ฝ๋ฌผ์ด ํšจ๊ณผ๊ฐ€ ์—†์„ ๊ฒฝ์šฐ โ†’ ๋‹ค๋ฅธ ๋ฉด์—ญ์–ต์ œ์ œ๋ฅผ ์‚ฌ์šฉ. ์ด๋•Œ ์Šคํ…Œ๋กœ์ด๋“œ ์•ฝ๋ฌผ์„ ํ•œ ๋ฒˆ์— ๋Š์œผ๋ฉด ์•ˆ ๋จ(์ฒด๋‚ด ํ•ฉ์„ฑ๋Ÿ‰ ์ค„์–ด๋“  ์ƒํƒœ), ์ ์ฐจ ์ค„์ด๋˜ ๋น ๋ฅด๊ฒŒ ํ•œ๋‹ค.
๊ด€๋ จ ๋ฌธ์„œ